Literature DB >> 2261200

Second primary tumors following thyroid cancer. A Swedish record-linkage study.

P Hall1, L E Holm, G Lundell.   

Abstract

The incidence of second primary tumors was studied through record-linkage in 2,968 thyroid cancer patients reported to the Swedish Cancer Registry during the period 1958-1975. The cohort was matched with the Swedish Cancer Registry between 1959 and 1984. A total of 283 second primary tumors were reported more than one year after thyroid cancer diagnosis, and the standardized incidence ratio (SIR) was 1.18 (95% confidence interval = 1.03-1.31). A significant elevated risk of cancer of the kidney, endocrine glands, and nervous system was noted. Men had a higher risk (SIR = 1.37; 95% CI = 1.06-1.70) than women (SIR = 1.11; 95% CI = 0.96-1.28). Patients who were 36-45 years at the time of the thyroid cancer diagnosis were at highest risk of developing a second primary tumor (SIR = 1.35; 95% CI = 0.99-1.81). Significantly elevated risks were seen 5-9 years after the thyroid cancer diagnosis (SIR = 1.44; 95% CI = 1:14-1.69), and the SIR was close to unity after greater than or equal to 15 years of followup. Previously described elevated risks of subsequent leukemia and breast cancer were not confirmed in this study. Close medical surveillance, thyroid cancer treatment, hereditary factors, and a high frequency of autopsy could all contribute to the elevated risk of a second primary tumor in these patients.

Entities:  

Mesh:

Year:  1990        PMID: 2261200     DOI: 10.3109/02841869009096381

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

1.  Risk of second malignancies among survivors of pediatric thyroid cancer.

Authors:  Marwan H Adly; Mohamed Sobhy; Mohamed A Rezk; Medhat Ishak; Mahmoud A Afifi; Ayman El Shafie; Mahmoud Ahmed Ali; Wael Zekri; Ahmad Samir Alfaar; Wafaa M Rashed
Journal:  Int J Clin Oncol       Date:  2018-02-28       Impact factor: 3.402

Review 2.  The impact of family history on non-medullary thyroid cancer.

Authors:  I J Nixon; C Suárez; R Simo; A Sanabria; P Angelos; A Rinaldo; J P Rodrigo; L P Kowalski; D M Hartl; M L Hinni; J P Shah; A Ferlito
Journal:  Eur J Surg Oncol       Date:  2016-08-11       Impact factor: 4.424

3.  Risk of second primary cancer following differentiated thyroid cancer.

Authors:  Emmanuelle Berthe; Michel Henry-Amar; Jean-Jacques Michels; Jean-Pierre Rame; Pascaline Berthet; Emmanuel Babin; Philippe Icard; Guy Samama; Françoise Galateau-Sallé; Jacques Mahoudeau; Stéphane Bardet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-28       Impact factor: 9.236

4.  Second primary malignancies in thyroid cancer patients.

Authors:  C Rubino; F de Vathaire; M E Dottorini; P Hall; C Schvartz; J E Couette; M G Dondon; M T Abbas; C Langlois; M Schlumberger
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

5.  Second primary neoplasms in thyroid cancer patients.

Authors:  K Ishikawa; S Noguchi; K Tanaka; A Fukuda; T Hirohata
Journal:  Jpn J Cancer Res       Date:  1996-03

Review 6.  Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.

Authors:  Christoph Reiners; Rita Schneider; Tamara Platonova; Mikhail Fridman; Uwe Malzahn; Uwe Mäder; Alexis Vrachimis; Tatiana Bogdanova; Jolanta Krajewska; Rossella Elisei; Fernanda Vaisman; Jasna Mihailovic; Gracinda Costa; Valentina Drozd
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-10       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.